AXDX Accelerate Diagnostics Inc

Price (delayed)

$5.31

Market cap

$326.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.43

Enterprise value

$437.88M

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC ...

Highlights
The revenue has grown by 18% year-on-year and by 6% since the previous quarter
Accelerate Diagnostics's EPS has increased by 4.7% YoY
The gross profit has decreased by 6% YoY but it has increased by 2.3% QoQ
AXDX's equity has shrunk by 89% YoY and by 5% QoQ
The gross margin fell by 20% YoY and by 3.4% QoQ

Key stats

What are the main financial stats of AXDX
Market
Shares outstanding
61.5M
Market cap
$326.56M
Enterprise value
$437.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
26.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.45
Earnings
Revenue
$12.01M
EBIT
-$67.35M
EBITDA
-$64.67M
Free cash flow
-$46.68M
Per share
EPS
-$1.43
Free cash flow per share
-$0.76
Book value per share
-$1.14
Revenue per share
$0.2
TBVPS
$1.54
Balance sheet
Total assets
$93.99M
Total liabilities
$163.74M
Debt
$155.91M
Equity
-$69.75M
Working capital
$74.38M
Liquidity
Debt to equity
-2.24
Current ratio
8.98
Quick ratio
7.61
Net debt/EBITDA
-1.72
Margins
EBITDA margin
-538.3%
Gross margin
36.6%
Net margin
-695.8%
Operating margin
-564.9%
Efficiency
Return on assets
-87%
Return on equity
N/A
Return on invested capital
-33.3%
Return on capital employed
-79.5%
Return on sales
-560.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXDX stock price

How has the Accelerate Diagnostics stock price performed over time
Intraday
-2.39%
1 week
-11.06%
1 month
-14.9%
1 year
-53.83%
YTD
-29.95%
QTD
-34.12%

Financial performance

How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$12.01M
Gross profit
$4.4M
Operating income
-$67.86M
Net income
-$83.58M
Gross margin
36.6%
Net margin
-695.8%
The gross margin fell by 20% YoY and by 3.4% QoQ
The revenue has grown by 18% year-on-year and by 6% since the previous quarter
Accelerate Diagnostics's operating margin has increased by 17% YoY and by 2.9% from the previous quarter
AXDX's net margin is up by 14% YoY and by 2.8% QoQ

Growth

What is Accelerate Diagnostics's growth rate over time

Valuation

What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
26.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.45
Accelerate Diagnostics's EPS has increased by 4.7% YoY
AXDX's equity has shrunk by 89% YoY and by 5% QoQ
AXDX's price to sales (P/S) is 97% less than its 5-year quarterly average of 812.8 and 38% less than its last 4 quarters average of 43.6
The revenue has grown by 18% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's ROA has decreased by 37% YoY and by 9% from the previous quarter
Accelerate Diagnostics's ROS has increased by 16% YoY and by 2.6% from the previous quarter
Accelerate Diagnostics's return on invested capital has decreased by 4.1% QoQ but it has increased by 2.9% YoY

Dividends

What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXDX.

Financial health

How did Accelerate Diagnostics financials performed over time
The company's total assets is 43% lower than its total liabilities
The company's current ratio fell by 19% QoQ and by 11% YoY
The company's total assets fell by 18% YoY
AXDX's equity has shrunk by 89% YoY and by 5% QoQ
Accelerate Diagnostics's debt to equity has increased by 42% YoY and by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.